Tag: Oncology
PharmaSignal — Oncology therapeutic area
Sidewinder secures $137M to advance ‘precision’ ADCs
BioPharma Dive
Backed by OrbiMed, Novartis venture arm and many other investors, the biotech is among those working on newer technology that could broaden the reach of antibody-drug conjugates.
Sidewinder pockets $137m in Series B to take bispecific ADCs to clinic
Pharmaceutical Technology
The funding round, led by Novartis and OrbiMed, will allow Sidewinder to progress its bispecific ADC programmes to the clinic.
CatalYm begins phase 2b trial of visugromab in second-line liver cancer treatment
PharmaTimes
Study expands development of the antibody into hepatocellular carcinoma
MSD secures EC clearance for Keytruda combination therapy for ovarian cancer
Pharmaceutical Technology
MSD has received the EC approval for Keytruda along with paclitaxel, with or without bevacizumab, as a treatment for PD-L1-positive ovarian cancer.
AZ claims another win for Imfinzi in frontline liver cancer
Pharmaphorum
AstraZeneca has built the case for Imfinzi in earlier-stage liver cancer with a second phase 3 trial readout in its EMERALD programme.
Telomir seeks FDA approval for Telomir-1 to treat breast cancer
Pharmaceutical Business Review
The IND includes results from completed toxicology, pharmacology, and manufacturing studies necessary for regulatory assessment.
Symeres and Ambagon collaborate for colorectal cancer molecules
Pharmaceutical Business Review
The partnership aims to explore a new class of small molecules, called molecular glues, which enable or stabilise interactions between proteins.
Telomir seeks FDA approval for Telomir-1 to treat breast cancer
Pharmaceutical Technology
Telomir Pharmaceuticals has submitted an IND application to the FDA for Telomir-1, its lead candidate targeting advanced and metastatic TNBC.
S16 Ep42: Variability and Innovation in Small Cell Lung Cancer Care: With Ticiana Leal, MD
OncLive Podcast
In today’s episode, we spoke with Ticiana Leal, MD, about variability in community practice and evolving treatment strategies for patients with small cell lung cancer (SCLC).
S16 Ep40: FDA Approval Insights: Zongertinib for HER2 TKD-Mutated NSCLC: With Julia Rotow, MD; and Martin Dietrich, MD, PhD
OncLive Podcast
In today’s episode, we spoke with Julia Rotow, MD, and Martin Dietrich, MD, PhD.
Amgen’s BiTE for lung cancer backed for EU approval
Pharmaphorum
Amgen’s fast-growing bispecific T-cell engager Imdylltra should be cleared as a second-line therapy for small cell lung cancer, said the CHMP.
S16 Ep38: Live Tumor Board: Precision Pathways Transforming Patient Care in Advanced NSCLC
OncLive Podcast
In this podcast, experts Narjust Florez, MD, FASCO; David Carbone, MD, PhD; and Edward Garon, MD, MS; discuss the use of KRAS-, NRG1-, MET-, and ROS1-targeting agents to transform patient care in adva